Maximally androgen blockade therapy
Shimazui, T.
Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 477-480
2011
ISSN/ISBN: 0047-1852 PMID: 22208027 Document Number: 649464
Document emailed within 1 workday
Related Documents
Labrie, F.; Bélanger, A.; Dupont, A.; Luu-The, V.; Simard, J.; Labrie, C. 1993: Science behind total androgen blockade: from gene to combination therapy Clinical and Investigative Medicine. Medecine Clinique et Experimentale 16(6): 475-492Kagebayashi, Y.; Ozono, S.; Takashima, K.; Yoshikawa, M.; Hayashi, Y.; Kaneko, Y.; Maruyama, Y.; Hirao, Y.; Okajima, E. 1997: Total androgen blockade for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 43(3): 197-201
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Akaza, H. 2005: Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality? Canadian Journal of Urology 12(Suppl 1): 77-80
Kirby, R.S. 1996: Maximal androgen blockade (MAB) for the treatment of prostate cancer British Journal of Clinical Practice 50(5): 287
Ozono, S.; Hirao, Y. 1998: Total androgen blockade--concept, theory, method and clinical application Nihon Rinsho. Japanese Journal of Clinical Medicine 56(8): 2129-2134
Dahmani, L.; Wagner, B.; Auzanneau, C.; Irani, J.; Doré, B. 2003: Prevalence of osteoporotic fractures in patients treated by androgen blockade for prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(1): 73-78
Fitzpatrick, J.M. 1996: Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against European Urology 29(Suppl): 37-39
Zhang, S.-g.; Wang, Y.-h.; Ding, Y.; Wu, Y. 2005: Long term survival results in advanced prostate cancer treated with combined androgen blockade Zhonghua Nan Ke Xue 11(10): 770
Neri, B.; Bartalucci, S.; Pieri, A.; Gemelli, M.T.; Rizzo, M.; Bartoletti, R.; Trippitelli, A.; Paoletti, M.C. 1989: Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects Anticancer Research 9(1): 13-16
Lo Re, G.; Buonadonna, A.; Duati, M.; Colussi, A.M.; Canzonieri, V.; Frustaci, S.; Morassut, S.; Cimitan, M.; Tumolo, S. 1999: Efficacy of total androgen blockade in metastatic prostatic carcinoma with transient hypogonadotropic hypogonadism: a case report Tumori 85(4): 280-283
Parra, A.; Barrón, J.; Mota-González, M.; Ibarra, V.; Espinosa de los Monteros, A. 1995: Serum androgen changes during meal-induced hyperinsulinemia and after acute sequential blockade and hyperstimulation of insulin release in women with polycystic ovary syndrome Archives of Medical Research 26(Special Issue): S209-S217
Nishihara, C.; Kuratsukuri, K.; Tanaka, T.; Kawashima, H.; Nakatani, T. 2011: Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases Hinyokika Kiyo. Acta Urologica Japonica 57(4): 209-212
Abi Aad, A.S.; Van Cangh, P.J. 1996: Intermittent androgen therapy Acta Urologica Belgica 64(2): 91-92
Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Yen, J-Lung.; Chang, K-Huey.; Sheu, J-Cherng.; Lee, Y-Jinn.; Tsai, L-Ping. 2005: Partial androgen insensitivity syndrome with R840H mutation in androgen receptor: report of one case Acta Paediatrica Taiwanica 46(2): 101-105
Carlsson, P.; Liss, P.-E. 2008: Maximally reduced suffering or care based on needs? Lakartidningen 105(19): 1412-1413; Discussion: 1413-1414
Nickel, B.; Schwartz, A.; Rosenmann, E.; Kaufman, M.; Pinsky, L.; Wrogemann, K. 1988: A study of androgen-resistant subjects indicates that the 6.7 pI/56 kDa protein in genital skin fibroblasts is related to the androgen receptor Clinical and Investigative Medicine. Medecine Clinique et Experimentale 11(1): 22-33
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699